Drug Profile
IMP 701
Alternative Names: ImmunTune IMP701 antagonist antibody - Immutep Limited; IMP701; IMP701 LAG-3 antibodyLatest Information Update: 03 Sep 2021
Price :
$50
*
At a glance
- Originator Immutep
- Developer Novartis
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Infections
Most Recent Events
- 03 Sep 2021 Discontinued - Phase-I/II for Cancer in USA (Parenteral) before September 2021 (Immutep Limited's pipeline, September 2021) (Novartis's pipeline, September 2021)
- 08 Jan 2019 IMP 701 is still in phaseI/II trials for Cancer in USA (Immutep pipeline, January 2019)
- 03 Dec 2018 Discontinued - Preclinical for Infections in USA (Parenteral)